help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on February 2, 2006, doi:10.1164/rccm.200511-1789OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200511-1789OCv1
173/10/1155    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scherpereel, A.
Right arrow Articles by Lassalle, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scherpereel, A.
Right arrow Articles by Lassalle, P.
American Journal of Respiratory and Critical Care Medicine Vol 173. pp. 1155-1160, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200511-1789OC

Original Article

Soluble Mesothelin–related Peptides in the Diagnosis of Malignant Pleural Mesothelioma

Arnaud Scherpereel*, Bogdan Grigoriu*, Massimo Conti{dagger}, Thomas Gey, Marc Grégoire, Marie-Christine Copin, Patrick Devos, Bachar Chahine, Henri Porte{dagger} and Philippe Lassalle

INSERM Unit 774, Institut Pasteur de Lille; Departments of Pulmonary and Thoracic Oncology, Thoracic Surgery, and Pathology, University Hospital of Lille; Department of Biostatistics, Medical School of Lille, Lille; INSERM U601, Nantes, France; and University of Medicine, Iasi, Romania

Correspondence and requests for reprints should be addressed to Arnaud Scherpereel, M.D., Ph.D., Clinique des Maladies Respiratoires, Hopital Calmette, CHRU of Lille, 59037 Lille Cedex, France. E-mail: a-scherpereel{at}chru-lille.fr

Background: Diagnosis of malignant pleural mesothelioma is a challenging issue. Potential markers in mesothelioma diagnosis include soluble mesothelin–related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet.

Methods: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma.

Findings: Mean serum SMRP level was higher in patients with mesothelioma (2.05 ± 2.57 nM/L [median ± interquartile range]) than in patients with metastasis (1.02 ± 1.79 nM/L) or benign lesions (0.55 ± 0.59 nM/L). The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80%, specificity = 82.6%). The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3%, specificity = 73.3%). SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 ± 83.2 nM/L; benign lesions: 6.4 ± 11.1 nM/L; metastasis: 6.36 ± 21.73 nM/L). The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7%, specificity = 76.2%). The AUC for pleural SMRP-differentiating metastasis and mesothelioma was 0.793.

Interpretation: We show that SMRPs may be a promising marker for mesothelioma diagnosis when measured either in serum or pleural fluid. The diagnostic value of SMRPs was similar in both types of samples, but pleural fluid SMRPs may better discriminate mesothelioma from pleural metastasis.

Key Words: diagnosis • marker • neoplasm • pleural disease




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
H. E. Davies, R. S. Sadler, S. Bielsa, N. A. Maskell, N. M. Rahman, R. J. O. Davies, B. L. Ferry, and Y. C. G. Lee
Clinical Impact and Reliability of Pleural Fluid Mesothelin in Undiagnosed Pleural Effusions
Am. J. Respir. Crit. Care Med., September 1, 2009; 180(5): 437 - 444.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
B. D. Grigoriu, B. Chahine, A. Vachani, T. Gey, M. Conti, D. H. Sterman, G. Marchandise, H. Porte, S. M. Albelda, and A. Scherpereel
Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment
Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 950 - 954.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E.-K. Park, P. S. Thomas, A. R. Johnson, and D. H. Yates
Osteopontin Levels in an Asbestos-Exposed Population
Clin. Cancer Res., February 15, 2009; 15(4): 1362 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Rodriguez Portal, E. Rodriguez Becerra, D. Rodriguez Rodriguez, I. Alfageme Michavila, A. Quero Martinez, C. Diego Roza, A. Leon Jimenez, I. Isidro Montes, and P. Cebollero Rivas
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 646 - 650.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E.-K. Park, P. S. Thomas, J. Creaney, A. R. Johnson, B. W. Robinson, and D. H. Yates
Blood-Based Early Detection of Malignant Mesothelioma
J. Clin. Oncol., January 1, 2009; 27(1): 160 - 160.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. P. van Meerbeeck and G. Hillerdal
Screening for Mesothelioma: More Harm than Good?
Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 781 - 782.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E.-K. Park, A. Sandrini, D. H. Yates, J. Creaney, B. W. Robinson, P. S. Thomas, and A. R. Johnson
Soluble Mesothelin-related Protein in an Asbestos-exposed Population: The Dust Diseases Board Cohort Study
Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 832 - 837.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
M. D. Johnson, F. Vito, and M. J. O'Connell
Mesothelin Expression in the Leptomeninges and Meningiomas
J. Histochem. Cytochem., June 1, 2008; 56(6): 579 - 585.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Shiomi, Y. Hagiwara, K. Sonoue, T. Segawa, K. Miyashita, M. Maeda, H. Izumi, K. Masuda, M. Hirabayashi, T. Moroboshi, et al.
Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for N-ERC/Mesothelin Increases its Potential as a Useful Serum Tumor Marker for Mesothelioma
Clin. Cancer Res., March 1, 2008; 14(5): 1431 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. Amati, M. Tomasetti, M. Scartozzi, L. Mariotti, R. Alleva, E. Pignotti, B. Borghi, M. Valentino, M. Governa, J. Neuzil, et al.
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 163 - 170.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
B D Grigoriu and A Scherpereel
Diagnostic value of soluble mesothelin in malignant mesothelioma
Thorax, January 1, 2008; 63(1): 87 - 88.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
H. L. Kindler, R. Bueno, and J. R. Testa
New Biomarkers, Surgical Controversies, and Rationally Targeted Therapies for Malignant Mesothelioma
ASCO Educational Book, January 1, 2008; 2008(1): 354 - 361.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
British Thoracic Society Standards of Care Committ
BTS statement on malignant mesothelioma in the UK, 2007
Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19.
[Full Text] [PDF]

Home page
 ChestHome page
J. Creaney, I. van Bruggen, M. Hof, A. Segal, A. W. Musk, N. de Klerk, N. Horick, S. J. Skates, and B. W. S. Robinson
Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma
Chest, October 1, 2007; 132(4): 1239 - 1246.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Cristaudo, R. Foddis, A. Vivaldi, G. Guglielmi, N. Dipalma, R. Filiberti, M. Neri, M. Ceppi, M. Paganuzzi, G. P. Ivaldi, et al.
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
Clin. Cancer Res., September 1, 2007; 13(17): 5076 - 5081.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
Y C G. Lee
Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?
Thorax, July 1, 2007; 62(7): 561 - 562.
[Full Text] [PDF]

Home page
 ThoraxHome page
J. Creaney, D. Yeoman, L. K Naumoff, M. Hof, A. Segal, A. W. Musk, N. De Klerk, N. Horick, S. J Skates, and B. W S Robinson
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
Thorax, July 1, 2007; 62(7): 569 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B.-D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, M. Gregoire, H. Porte, M.-C. Copin, and P. Lassalle
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
Clin. Cancer Res., May 15, 2007; 13(10): 2928 - 2935.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
H. L. Beyer, R. D. Geschwindt, C. L. Glover, L. Tran, I. Hellstrom, K.-E. Hellstrom, M. C. Miller, T. Verch, W. J. Allard, H. I. Pass, et al.
MESOMARKTM: A Potential Test for Malignant Pleural Mesothelioma
Clin. Chem., April 1, 2007; 53(4): 666 - 672.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society 		  New Orleans Int'l Conf